logo

Neos Therapeutics, Inc. (NEOS)



Trade NEOS now with
  Date
  Headline
3/14/2019 7:22:21 AM Neos Therapeutics Q4 Loss Per Share $0.23 Vs Loss $0.47 Last Year
1/30/2019 8:05:18 AM Neos Therapeutics Appoints James Robinson To Board Of Directors
12/26/2018 7:32:10 AM Neos Therapeutics Announces Settlement With Teva On Cotempla XR-ODT Patent Litigation
11/27/2018 9:04:00 AM Altimmune Appoints Vipin Garg As Its President And CEO Succeeding Bill Enright
11/9/2018 7:10:50 AM Neos Therapeutics Q3 Net Loss $12.7 Mln Or $0.43/Shr Vs Loss Of $16.3 Mln Or $0.58/shr Last Year
11/6/2018 9:22:10 AM Neos Therapeutics Announces Pricing Of Underwritten Public Offering Of $40 Mln Of Common Stock
11/5/2018 4:04:32 PM Neos Therapeutics Announces Proposed Offering Of Common Stock
10/23/2018 8:12:50 AM Neos Therapeutics Licenses Pipeline Candidate For Treatment Of Sialorrhea
8/8/2018 7:07:11 AM Neos Therapeutics Q2 Net Loss $15.2 Mln Or $0.52/shr Vs. Net Loss $18.6 Mln Or $0.82/shr Last Year
6/27/2018 4:32:54 PM Neos Therapeutics Appoints Jerry McLaughlin As CEO
5/9/2018 7:17:16 AM Neos Therapeutics Q1 Net Loss $14.4 Mln Or $0.50/Shr Vs Loss Of $17.2 Mln Or $0.88/Shr Last Year
3/15/2018 7:10:31 AM Neos Therapeutics Q4 Net Loss $14.2 Mln Or $0.49/Shr Vs Loss $18.4 Mln Or $1.14/SAhr Last Year
2/26/2018 8:19:59 AM Neos Therapeutics Launches Adzenys ER Oral Suspension In U.S. For Treatment Of ADHD In Patients 6 Years And Older
2/20/2018 10:04:24 AM Neos Therapeutics Reiterates Confidence In Strategic Plan And Value Creation Opportunities
2/20/2018 7:03:33 AM PDL BioPharma To No Longer Pursue Its Proposed Acquisition Of Neos Therapeutics
9/4/2015 9:09:05 AM RBC Capital Markets Is Cutting Neos Therapeutics, Inc. (NEOS) FY16 Estimate To -3.74 From -3.68
  
 
>